You are here
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
PA-21-260: PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)Release Date: 07-08-2021Open Date: 08-06-2021 Due Dates: Multiple Close Date: 04-06-2022
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44- Clinical Trial Not Allowed)Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022
Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022
A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health